{"entity":{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Daiichi Sankyo, now recruiting.","summary":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT04145622 by Daiichi Sankyo, with 250 participants planned, started 2019-11-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Ifinatamab deruxtecan (I-DXd).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04145622","url":"https://clinicaltrials.gov/study/NCT04145622"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ifinatamab-deruxtecan"],"companies":["daiichi-sankyo","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04145622","phase":"1/2","setting":"Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)","sponsor":"Daiichi Sankyo","enrolled":250,"outcomes":[]},"route":"/trials/nct04145622/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}